Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Liabilities: 2019-2024

Historic Other Non-Current Liabilities for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $7.8 million.

  • Allogene Therapeutics' Other Non-Current Liabilities rose 101.87% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 101.87%. This contributed to the annual value of $7.8 million for FY2024, which is 49.86% up from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' Other Non-Current Liabilities is $7.8 million, which was up 49.86% from $5.2 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Other Non-Current Liabilities registered a high of $7.8 million during FY2021, and its lowest value of $3.1 million during FY2020.
  • For the 3-year period, Allogene Therapeutics' Other Non-Current Liabilities averaged around $6.3 million, with its median value being $5.8 million (2022).
  • Per our database at Business Quant, Allogene Therapeutics' Other Non-Current Liabilities dropped by 29.14% in 2020 and then soared by 152.74% in 2021.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Other Non-Current Liabilities stood at $3.1 million in 2020, then spiked by 152.74% to $7.8 million in 2021, then fell by 24.96% to $5.8 million in 2022, then fell by 11.42% to $5.2 million in 2023, then soared by 49.86% to $7.8 million in 2024.